[Do drug-eluting stents influence the spectrum of coronary artery bypass surgery?].
BACKGROUND
The number of surgical coronary revascularization procedures is static and even declining. Since the introduction of drug eluting stents the question arose whether this will have an impact on the spectrum of surgical coronary revascularization procedures.
Bypass surgery is a routine procedure for the treatment of coronary artery disease with good results. Studies have shown that there is a benefit in favor of surgery compared to interventional cardiologic procedures. DRUG-ELUTING STENTS: In recent studies a new generation of stents, drug-eluting stents, have proven to have a significant better patency rate than common stents. However, to date there are no studies which show a benefit compared to surgery given the same indication for treatment.


CONCLUSIONS
Therefore, the question whether drug-eluting stents have an impact on the spectrum of bypass surgery cannot be fully answered at present.
Matschke
Klaus
K
Klinik für Herz- und Thorakale Gefässchirurgie, Herzzentrum Dresden GmbH, Universitätsklinik, Dresden. monika.webre.hkz_dd@t-online.de
Tugtekin
Sems Malte
SM
Kappert
Utz
U
Jung
Friedrich
F
Park
Jai-Wun
JW
Knaut
Michael
M
D000287:Administration, Topical; D015906:Angioplasty, Balloon, Coronary / Q000295:instrumentation*; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D020099:Coated Materials, Biocompatible; D001026:Coronary Artery Bypass; D023903:Coronary Restenosis / Q000175:diagnosis / Q000517:prevention & control*; D023921:Coronary Stenosis / Q000175:diagnosis / Q000628:therapy*; D003331:Coronary Vessels / Q000187:drug effects; D019544:Equipment Failure Analysis; D006801:Humans; D008855:Microscopy, Electron, Scanning; D017239:Paclitaxel / Q000008:administration & dosage*; D020123:Sirolimus / Q000008:administration & dosage*; D015607:Stents; D016896:Treatment Outcome
D000903:Antibiotics, Antineoplastic; D000972:Antineoplastic Agents, Phytogenic; D020099:Coated Materials, Biocompatible; D017239:Paclitaxel; D020123:Sirolimus